Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 15 Nov 2026

ALKEM, full dossier

On a consolidated basis, for the quarter ended September 2026 compared with the quarter ended September 2025, Alkem Laboratories' net sales increased 13.77% to Rs 4551.99 crore.

7 publishers have reported this development. Each act of reporting is below, cited.

The record

On a consolidated basis, for the quarter ended September 2026 compared with the quarter ended September 2025, Alkem Laboratories' net sales increased 13.77% to Rs 4551.99 crore.

Alkem Laboratories' consolidated net profit fell 11.8% to ₹675 crore in Q2 FY27, compared to a profit of ₹765 crore in the same quarter of the previous fiscal year.

zeebiz.com12 Nov 2026

Net profit of Alkem Laboratories declined 11.73% to Rs 675.34 crore in the quarter ended September 2026 as against Rs 765.06 crore during the previous quarter ended September 2025.

Alkem Laboratories reported a 14.37 per cent decline in consolidated net profit to Rs 667.13 crore during the September quarter.

moneycontrol.com13 Nov 2026

Alkem Laboratories saw a drop in its consolidated net profit of close to 12 per cent at ₹675 crore, for the second quarter ended September 30, 2026.

Alkem Laboratories' second-quarter net profit declined 14.37% year-on-year to ₹667 crore as expenses rose, while revenue from operations increased 13.8% to ₹4,552 crore.

Alkem Laboratories reported an 11.8% year-on-year decline in consolidated net profit to Rs 675 crore in the September quarter of financial year 2027.

ndtvprofit.com12 Nov 2026

Alkem Laboratories reported a 14% revenue growth in Q2 FY27, but net profit fell 12% year on year, with EBITDA margin narrowing 50 basis points and shares declining 4%.

cnbctv18.com12 Nov 2026

Alkem Laboratories' net profit decreased by 11.8% to Rs 675 crore in Q2, while revenue increased by 13.8% to Rs 4,552 crore.

ndtvprofit.com12 Nov 2026

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.